Clinical trials: Neoplasms, Oral
Tongue Neoplasms, Tongue Cancer
Prosthesis Guided Speech Rehabilitation of T1/T2 Cancers of the Tongue
This study will fill a scientific gap in the current knowledge providing data for evaluation of the palatal augmentation prosthesis (PAP) as a therapeutic modality post-surgery.
- Conditions
- Tongue Neoplasms, Tongue Cancer, Oral Cancer
- Trial name
- PGSRT (NCT02584270)
- Testing
- Palatal Augmentation Prosthesis (PAP), Articulation Therapy
- Where
- United States
- Volunteers
- 40 people
- Sponsor
- University of Michigan
Anal Carcinoma, Cervical Carcinoma
Extended Follow Up of Young Women in Costa Rica Who Received Vaccine for Human Papillomavirus Types 16 and 18 and Unvaccinated Controls
This research trial studies extended follow up of young women in Costa Rica who received vaccine for human papillomavirus types 16 and 18 and unvaccinated controls.
- Conditions
- Anal Carcinoma, Cervical Carcinoma, Human Papillomavirus Infection, Human Papillomavirus-Related Cervical Carcinoma
- Trial name
- NCT00867464
- Testing
- Cytology Specimen Collection Procedure, Laboratory Biomarker Analysis, Long-term Follow-up
- Where
- Costa Rica
- Volunteers
- 8,670 people, healthy volunteers welcome
- Sponsor
- National Cancer Institute (NCI)
Oral Mucositis, Head and Neck Neoplasms
Ozone Therapy for the Treatment of Oral Mucositis in Patients Undergoing Radio and Chemotherapy in the Head and Neck Region
The present study aims to evaluate the effectiveness of a combined protocol of professional and at-home ozone therapy in the treatment of oral mucositis in patients undergoing radio- and/or chemotherapy.
- Trial name
- NCT07247799
- Testing
- Ozone treatment
- Where
- Italy
- Volunteers
- 38 people
- Sponsor
- Andrea Scribante
Parotid Tumor, Parotid Neoplasms
Trident Landmark as a Safe and Easy Method for Facial Nerve Trunk Identification During Superficial Parotidectomy
The parotid has a close relationship with the extra temporal course of the facial nerve. The study aimed to evaluate the accuracy and safety of trident landmark during superficial parotidectomy in the identification of the facial…
- Conditions
- Parotid Tumor, Parotid Neoplasms, Surgery, Head and Neck Disorder
- Trial name
- NCT04803032
- Testing
- Superficial parotidectomy
- Where
- Egypt
- Volunteers
- 60 people
- Sponsor
- Kafrelsheikh University
Advanced Solid Tumors, Selected Solid Tumors
Safety, Pharmacokinetics and Pharmacodynamics of BKM120 Plus MEK162 in Selected Advanced Solid Tumor Patients
This is an open label, dose finding, phase Ib clinical trial to determine the maximum tolerated dose (MTD) and/or the recommended phase II dose (RP2D) of the orally administered phosphatidylinositol 3'-kinase (PI3K) inhibitor…
- Trial name
- NCT01363232
- Testing
- BKM120 + MEK162
- Where
- 12 sites in United States, Canada and 5 more
- Volunteers
- 89 people
- Sponsor
- Array Biopharma, now a wholly owned subsidiary of Pfizer
Head and Neck Basaloid Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma
Ficlatuzumab w/wo Cetuximab in Patients w/Cetuximab-Resistant, Recurrent or Metastatic Head/Neck Squamous Cell Carcinoma
This randomized phase II trial studies how well ficlatuzumab with or without cetuximab works in treating patients with head and neck squamous cell carcinoma that has come back or spread to other places in the body and resistant…
- Conditions
- Head and Neck Basaloid Carcinoma, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Oropharyngeal Squamous Cell Carcinoma, Squamous Cell Carcinoma of Unknown Primary Origin
- Trial name
- NCT03422536
- Testing
- Cetuximab, Ficlatuzumab
- Where
- 6 sites in United States
- Volunteers
- 78 people
- Sponsor
- University of Arizona
Gynecologic Cancer, Venous Thromboembolism
Oral Apixaban (Eliquis) Versus Enoxaparin (Lovenox) for Thromboprophylaxis in Women With Suspected Pelvic Malignancy
The study will evaluate the incidence of major bleeding (including clinically relevant non-major (CRNM) bleeding) events in women undergoing surgery for gynecologic cancer with apixaban 2.5 mg twice a day (BID) compared to…
- Trial name
- NCT02366871
- Testing
- Oral apixaban, Subcutaneous enoxaparin
- Where
- 2 sites in United States
- Volunteers
- 400 people
- Sponsor
- University of Colorado, Denver
Solid Tumors
Phase 1 Study Of Aurora Kinase Inhibitor PF-03814735 In Patients With Advanced Solid Tumors
The purpose of this study is to determine the maximum tolerated dose and recommended phase 2 dose of PF-03814735 administered orally as single agent in patients with advanced solid tumors.
- Trial name
- NCT00424632
- Testing
- PF-03814735
- Where
- 2 sites in United States, Belgium
- Volunteers
- 57 people
- Sponsor
- Pfizer
Analgesic, Enhanced Recovery After Surgery
Acetaminophen Before Surgery Lowers Postop Pain in Pediatric Solid Tumor Patients (ERAS)
Pain is the predominant subjective symptom experienced during the perioperative period in pediatric patients with solid tumors. Intense pain may impede early postoperative activities and delay the recovery process.
- Conditions
- Analgesic, Enhanced Recovery After Surgery, Postoperative Pain, Acetaminophen
- Trial name
- NCT07095816
- Testing
- Acetaminophen, Sterilized water
- Where
- China
- Volunteers
- 182 people
- Sponsor
- Nanjing Children's Hospital
Neoplasms
A First-In-Human Study of RO5503781 in Participants With Advanced Malignancies Except Leukemia
This multicenter, open label, dose-escalating study will evaluate the safety, pharmacokinetics, pharmacodynamics, and efficacy of RO5503781, administered once daily (QD) or once weekly (QW) in participants with advanced…
- Trial name
- NCT01462175
- Testing
- RO5503781
- Where
- 8 sites in Australia, Canada and 3 more
- Volunteers
- 99 people
- Sponsor
- Hoffmann-La Roche
Squamous Cell Carcinoma
Human Papillomavirus on Oral Tissue, Saliva and Serum
Human papillomavirus (HPV) is one of the most prevalent infections in the world with several millions of new cases diagnosed yearly.
- Trial name
- CDHPOTSS (NCT01043328)
- Where
- Brazil
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- UPECLIN HC FM Botucatu Unesp
Breast Cancer
A Phase II Trial Testing Oral Administration of Lucitanib in Patients With Fibroblast Growth Factor Receptor (FGFR)1-amplified or Non-amplified Estrogen Receptor Positive Metastatic Breast Cancer
The aim of the study is to evaluate the objective response rate (ORR) of single agent lucitanib in metastatic breast cancer patients with FGFR1-amplified, FGFR1-non amplified with 11q amplification, or FGFR1-non amplified without…
- Trial name
- FINESSE (NCT02053636)
- Testing
- lucitanib
- Where
- 29 sites in Australia, Belgium and 7 more
- Volunteers
- 76 people
- Sponsor
- Institut de Recherches Internationales Servier
Radiation-Induced Mucositis
The Effect of Alpha Lipoic Acid on the Incidence and Severity of Radiotherapy-Induced Oral Mucositis in Head and Neck Cancer Patients
A prospective, randomized, controlled, single-blinded study will be conducted at Clinical Oncology department, Ain Shams University Hospitals, assessing the effect of Alpha Lipoic Acid on the incidence and severity of…
- Trial name
- NCT05023863
- Testing
- Alpha Lipoic Acid 600 MG Oral Tablets, radiation or concurrent chemoradiation
- Where
- Egypt
- Volunteers
- 70 people
- Sponsor
- Ain Shams University
Acute Myeloid Leukemia (AML)
PKC412, Daunorubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
RATIONALE: PKC412 may stop the growth of cancer cells by blocking the enzymes necessary for their growth. It may also increase the effectiveness of daunorubicin and cytarabine by making cancer cells more sensitive to the drugs.
- Trial name
- NCT00093600
- Testing
- cytarabine, daunorubicin hydrochloride, midostaurin
- Where
- 6 sites in United States, Germany
- Volunteers
- 69 people
- Sponsor
- Novartis Pharmaceuticals
Head and Neck Cancer
Combination Chemotherapy and Radiation in Treating Patients With Stage III or IV Head and Neck Cancer (Paradigm Trial)
RATIONALE: Drugs used in chemotherapy, such as docetaxel, cisplatin, fluorouracil, and carboplatin, work in different ways to stop tumor cells from dividing so they stop growing or die.
- Trial name
- NCT00095875
- Testing
- carboplatin, cisplatin, docetaxel
- Where
- 15 sites in United States, Germany
- Volunteers
- 145 people
- Sponsor
- Dana-Farber Cancer Institute
Malignant Neoplasms of Lip Oral Cavity and Pharynx, Oropharyngeal Cancer
Trial of Magnetic Resonance Imaging Guided Radiotherapy Dose Adaptation in Human Papilloma Virus Positive Oropharyngeal Cancer
The goal of this clinical research study is to compare the use of MRI simulations to plan different doses of intensity modulated radiotherapy (IMRT) to the standard IMRT dose in patients with low risk human papilloma virus…
- Trial name
- NCT03224000
- Testing
- Modified Barium Swallow (MBS), Swallowing Questionnaire, Symptom Questionnaire
- Where
- United States
- Volunteers
- 90 people
- Sponsor
- M.D. Anderson Cancer Center
Psoriasis
A Study To Evaluate The Effects And Safety Of Treatment, Treatment Withdrawal, Followed By Re-Treatment With CP-690,550 In Subjects With Moderate To Severe Chronic Plaque Psoriasis
The primary objectives of the study are to 1) compare the efficacy responses of CP 690,550 (5 mg BID and 10 mg BID) versus placebo following 24 weeks of CP 690,550 treatment and subsequent withdrawal of active treatment at…
- Trial name
- NCT01186744
- Testing
- CP-690,550
- Where
- 87 sites in United States, Argentina and 10 more
- Volunteers
- 666 people
- Sponsor
- Pfizer
Advanced Cancer, Advanced Solid Tumor
A Study of Oral 7HP349 (Alintegimod) in Combination With Ipilimumab Followed by Nivolumab Monotherapy
This study is an open-label Phase Ib (Part A) dose escalation followed by a blinded, randomized, multi cohort Phase 2a (Part B) comparison of combination vs. reference regimens.
- Conditions
- Advanced Cancer, Advanced Solid Tumor, Melanoma, Metastasis
- Trial name
- NCT06362369
- Testing
- Alintegimod, Ipilimumab, Nivolumab
- Where
- 5 sites in United States
- Volunteers
- 126 people
- Sponsor
- 7 Hills Pharma, LLC
Cancer, Sarcoma
Safety, Tolerability and Maximum Tolerated Dose of Oral AP23573 in Combination With Doxorubicin (8669-015)
This study is designed to determine the safety, tolerability and maximum tolerated dose of Oral AP23573 in combination with Doxorubicin
- Trial name
- NCT00288431
- Testing
- ridaforolimus, Doxorubicin
- Volunteers
- 37 people
- Sponsor
- Merck Sharp & Dohme LLC
Squamous Cell Carcinoma of the Oral Cavity
Pharmacokinetic (PK) Analysis of Antitumor B in Patients With Oral Cancer
A Window of Opportunity Clinical Trial. This study design permits examination of effects of an oral agent on cancer patients during the "window" between diagnosis of their cancer and their definitive cancer surgery.
- Trial name
- NCT03459729
- Testing
- Antitumor B
- Where
- United States
- Volunteers
- 6 people
- Sponsor
- Medical College of Wisconsin